[Chemotherapy and hormonotherapy of breast cancers].
The interest of adjuvant chemotherapy and hormonotherapy is now established in breast cancer. Their indications are more and more precise, even though progresses are still warranted to better take into account the prognostic factors in treatment strategies. Metastatic breast cancer is essentially incurable. However, a standard therapy given according to the clinical and biological presentation is able to insure acceptable response rate, overall survival and quality of life. For these reasons, innovative strategies may be evaluated under good medical practice conditions and considered as an ethical obligation.
Médecine oncologique Institut Curie, Paris.
P
P
Pouillart
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal
Chimiothérapie et hormonothérapie des cancers du sein.